CBD and TBI
Research Study
The LUNA study is recruiting participants who are interested in using cannabinoids (CBD) to reduce symptoms of their traumatic brain injuries (TBI). Join our compensated study today!
Fast Facts
diagnosed with a Traumatic brain injury
18-60 Years old
Compensation Provided
Conducted in denver metro area
Study Background
Traumatic brain injuries can negatively affect your work life, interpersonal relationships, and independent living, and they can be difficult to treat. The chronic symptoms of a TBI can respond in many different ways to one treatment, and TBI patients often receive numerous therapies that may not work.
There is a growing awareness of cannabidiol (CBD) as a possible treatment for TBI, but limited scientific evidence so far. That’s where our study comes in. We want to investigate how CBD affects symptoms of TBI.
Your participation in this study may help researchers improve treatment approaches for TBI. Further research today and join our compensated study!
Study Background
Traumatic brain injuries can negatively affect your work life, interpersonal relationships, and independent living, and they can be difficult to treat. The chronic symptoms of a TBI can respond in many different ways to one treatment, and TBI patients often receive numerous therapies that may not work.
There is a growing awareness of cannabidiol (CBD) as a possible treatment for TBI, but limited scientific evidence so far. That’s where our study comes in. We want to investigate how CBD affects symptoms of TBI.
Your participation in this study may help researchers improve treatment approaches for TBI. Further research today and join our compensated study
Additional Information
You may qualify for this study if you meet the following criteria.
Inclusion Criteria:
- Diagnosed with a Traumatic Brain Injury
- 18-60 years old
- Able to provide informed consent
Exclusion Criteria:
- Currently in litigation for your TBI
- Use of recreational drugs (cocaine, opiates, meth, MDMA) in the past 60 days
If you join the study, you will be randomized to receive one of three study medications that you will take for a period of 12 weeks:
- 210 mg/day of CBD that includes trace amounts of THC (< 0.3%),
- 210 mg/day of CBD that includes no THC, or
- 210 mg/day of Hemp Seed Oil, which does not contain any CBD or THC.
You will not know which medication group you are in.
There will be a study visit approximately each week during the 12-week period you are taking the study medication. The first study visit will take place at the University of Colorado Anschutz Medical Campus (AMC). There will be three more in-person study appointments at AMC. You will complete weekly surveys during each remaining week during the 12-week period. Visits may include a breathalyzer test, a blood draw, a urine drug and pregnancy screen, cognitive tasks, and surveys and questionnaires, depending on the week.
Total study participation will last 12 weeks.
